中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HY257336 |
|---|---|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG |
| 클론 ID | DXL625 |
| 생물학적 활성 | DXL625 (1-25 ug/mL; 24 h, 48 h) induces dose-dependent and time-dependent reductions in ATP content in Ramos Burkitt’s lymphoma cells, with greater potency than Rituxan at all tested concentrations (1, 5, 10, 25 ug/mL) after 24 and 48 hours of treatment [1]. DXL625 (1-25 ug/mL; 24 h) induces dose-dependent caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 30.0% of cells undergoing apoptosis at the highest tested concentration (25 ug/mL) after 24 hours of treatment [1]. DXL625 (10 ug/mL; 24 h) induces caspase-mediated apoptosis in Ramos Burkitt’s lymphoma cells, with 24.2% of cells testing positive for activated caspases after 24 hours of treatment with 10 ug/mL DXL625 [1]. DXL625 (10 ug/mL; 2 h) induces complement-dependent cytotoxicity in Ramos Burkitt’s lymphoma cells, resulting in 56.5% cell death after 2 hours of treatment with 10 ug/mL DXL625 in the presence of 5% (v/v) rabbit complement sera [1]. DXL625 (10 ug/mL; 2 h) retains complement-dependent cytotoxicity activity against primary CD19 + B-lymphocytes from healthy donor peripheral blood lymphocytes, reducing the CD19 + population to 3.1% after 2 hours of treatment with 10 ug/mL DXL625 in the presence of 5% (v/v) rabbit complement sera [1]. DXL625 (10 ug/mL; 24 h) induces enhanced NK cell-mediated antibody-dependent cellular cytotoxicity in Ramos Burkitt’s lymphoma cells, reducing normalized cell viability to 0.56 after 24 hours of treatment with 10 ug/mL DXL625 at a 6:1 effector-to-target ratio [1]. . Reduced cellular ATP content by 36.5%, 46.3%, 48.3%, and 48.5% at concentrations of 1, 5, 10, and 25 ug/mL, respectively, after 48 hours compared to vehicle-treated cells. |
| 타겟 | B-lymphocyte antigen CD20, B-lymphocyte surface antigen B1, Bp35, CD20, Leukocyte surface antigen Leu-16, MS4A1, Membrane-spanning 4-domains subfamily A member 1 |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | P11836 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | DXL625 |
| 배경 | B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva). 1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111 2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015 3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739 4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602 |
| 참고 문헌 | 1. Bingaman MG, et al. The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis. Anticancer Drugs. 2010;21(5):532-542. [HY257336] |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Anti-Human CD20/MS4A1 (DXL625)
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
